ATE154759T1 - Mycobacterium als adjuvans für antigene - Google Patents

Mycobacterium als adjuvans für antigene

Info

Publication number
ATE154759T1
ATE154759T1 AT91919563T AT91919563T ATE154759T1 AT E154759 T1 ATE154759 T1 AT E154759T1 AT 91919563 T AT91919563 T AT 91919563T AT 91919563 T AT91919563 T AT 91919563T AT E154759 T1 ATE154759 T1 AT E154759T1
Authority
AT
Austria
Prior art keywords
mycobacterium
antigens
adjuvant
immunoregulatry
vaccae
Prior art date
Application number
AT91919563T
Other languages
English (en)
Inventor
Graham Arthur William Rook
John Lawson Stanford
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909024282A external-priority patent/GB9024282D0/en
Priority claimed from GB919115410A external-priority patent/GB9115410D0/en
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE154759T1 publication Critical patent/ATE154759T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91919563T 1990-11-08 1991-11-08 Mycobacterium als adjuvans für antigene ATE154759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909024282A GB9024282D0 (en) 1990-11-08 1990-11-08 Antigen carrier
GB919115410A GB9115410D0 (en) 1991-07-17 1991-07-17 Antigen carrier

Publications (1)

Publication Number Publication Date
ATE154759T1 true ATE154759T1 (de) 1997-07-15

Family

ID=26297923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919563T ATE154759T1 (de) 1990-11-08 1991-11-08 Mycobacterium als adjuvans für antigene

Country Status (11)

Country Link
US (1) US5599545A (de)
EP (1) EP0556248B1 (de)
JP (1) JPH06501479A (de)
AT (1) ATE154759T1 (de)
AU (1) AU660430B2 (de)
CA (1) CA2095855C (de)
DE (1) DE69126668T2 (de)
DK (1) DK0556248T3 (de)
ES (1) ES2104731T3 (de)
GR (1) GR3024750T3 (de)
WO (1) WO1992008488A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
BR9406496A (pt) * 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
ES2171454T3 (es) 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
JP4358306B2 (ja) * 1996-12-18 2009-11-04 スタンフォード ルーク リミティド 免疫系のＴｈ２活性のダウン−レギュレーションのためのマイコバクテリア・ワクチン
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
WO1998047520A1 (en) * 1997-04-24 1998-10-29 Lovelace Respiratory Research Institute Prevention and treatment of allergic disease by targeted development of protective t-helper lymphocyte immunity
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
BR9907228A (pt) * 1998-01-23 2000-10-24 Nat Jewish Med & Res Center Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
WO1999042121A1 (en) 1998-02-20 1999-08-26 University Of Miami Modified heat shock protein-antigenic peptide complex
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) * 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20040247622A1 (en) * 1999-06-02 2004-12-09 Genesis Research And Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
EP1229931A4 (de) * 1999-10-07 2003-05-28 Corixa Corp Fusionsproteine aus mycobacterium tuberculosis
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1286693A4 (de) 2000-06-02 2005-07-13 Univ Connecticut Health Ct Komplexe aus alpha-2-makroglobulin und antigenen molekülen zur immuntherapie
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
CN1635896A (zh) 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
WO2004026024A2 (en) * 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
EP2258441A3 (de) * 2005-09-02 2011-09-21 Intercell USA, Inc. Vorrichtungen für die transkutane Abgabe von Vakzinen und transdermale Abgabe von Arzneimitteln
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (de) * 1971-11-19 1975-02-07 Anvar
NL7308450A (de) * 1972-06-20 1973-12-27
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4930169A (en) * 1988-12-27 1990-06-05 Kenneth Davison Apparatus for patient hydrotherapy and manipulative treatment by a therapist
DE69027112T2 (de) * 1989-01-23 1997-01-09 Auspharm International Ltd 4Th Impfstoffzusammensetzung
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
DK0556248T3 (da) 1997-10-27
AU660430B2 (en) 1995-06-29
US5599545A (en) 1997-02-04
ES2104731T3 (es) 1997-10-16
JPH06501479A (ja) 1994-02-17
CA2095855C (en) 2003-04-29
WO1992008488A1 (en) 1992-05-29
CA2095855A1 (en) 1992-05-09
DE69126668T2 (de) 1997-10-23
EP0556248A1 (de) 1993-08-25
EP0556248B1 (de) 1997-06-25
AU8874191A (en) 1992-06-11
GR3024750T3 (en) 1997-12-31
DE69126668D1 (de) 1997-07-31

Similar Documents

Publication Publication Date Title
DE69126668D1 (de) Mycobacterium als adjuvans für antigene
SE9103183L (sv) Virus-antikroppskomplex
DE69133345T2 (de) Gegen Diptere aktives, neues Bacillus-thuringiensis Isolat
EP0553244A4 (de)
GB1502774A (en) Immunological preparations
SE7700098L (sv) Bedovningsmedel och forfarande for framstellning derav
DK0530285T3 (da) Fremgangsmåde til enantioselektiv fremstilling af phenylisoserinderivater
LU88290I2 (de) Gestoden (Femovan / Femodene)
GR3003221T3 (en) Remedy against insects and mites
ATE108526T1 (de) Dichtung für gasisolationsklappen.
ES539683A0 (es) Procedimiento para la preparacion de 6,6-etilen-15,16-meti- len-3-oxo-17&-pregn-4-en-21,17-carbolactonas
ATE13086T1 (de) Reibkupplung.
ES8505049A1 (es) Disposicion de montaje de tope de desembrague, especialmente para vehiculo automovil
ES2062805T3 (es) Procedimiento para la preparacion de sulfatos ciclicos.
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
CA2249663A1 (en) New spirocyclic compounds
SE8206886D0 (sv) Anordning for uppberning av en person
FI922710A0 (fi) Eliminering av aktiverade lymfocyter.
Tamura et al. Effects of pertussis toxin (PT) on T-cell populations sensitized for delayed-type hypersensitivity in mice
Lind Serological studies of mycobacteria by means of diffusion-in-gel techniques. VI. Physical, chemical and immunological characteristics of precipitinogenic factors in an antigenic preparation from a culture filtrate of a virulent strain of M. tuberculosis
SU1398393A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к микобактериям туберкулеза
FI102973B1 (fi) Menetelmä 17-oksosteroidien valmistamiseksi
SU1280851A1 (ru) 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
JPS5214163A (en) Friction clutch
JPS57111496A (en) Module supporting device for timepiece

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee